Should chronic inflammatory demyelinating polyneuropathy be considered in a patient with relapsing‑remitting multiple sclerosis, well‑controlled focal seizures on clonazepam 0.5 mg at bedtime and pregabalin 150 mg twice daily, a history of anticonvulsant hypersensitivity, persistent brain‑fog with mild cognitive decline, and no peripheral weakness, sensory loss, or areflexia?

CIDP Should Not Be Considered in This Patient

Based on the clinical presentation described—absence of peripheral weakness, sensory loss, or areflexia—chronic inflammatory demyelinating polyneuropathy (CIDP) is not an appropriate diagnostic consideration, as these peripheral nerve findings are essential diagnostic features of CIDP. 1, 2

Essential Clinical Features Required for CIDP Diagnosis

CIDP is fundamentally defined by specific peripheral nerve manifestations that are absent in this patient:

• Motor involvement is mandatory: Typical CIDP presents with symmetric proximal AND distal muscle weakness affecting the extremities 1, 2
• Sensory abnormalities are expected: Motor-dominant manifestations still include sensory involvement in the peripheral distribution 1
• Areflexia or hyporeflexia is characteristic: Reduced or absent deep tendon reflexes are a hallmark finding due to demyelination affecting nerve roots and distal terminals 1, 3

Why This Patient Does Not Fit CIDP

The clinical scenario describes:

• No peripheral weakness: CIDP requires demonstrable muscle weakness in the extremities
• No sensory loss: Peripheral sensory deficits would be expected
• No areflexia: Absent or reduced reflexes are fundamental to the diagnosis
• Brain fog and cognitive decline: These are CNS symptoms consistent with the established MS diagnosis, not peripheral neuropathy 4, 5

The patient's symptoms (brain fog, mild cognitive decline) are attributable to their known relapsing-remitting multiple sclerosis, which commonly causes cognitive dysfunction 4, 5.

When CIDP and MS Can Coexist (But This Isn't That Scenario)

While the combination of MS and CIDP has been documented, it remains exceedingly rare and requires clear evidence of BOTH conditions 3:

• Temporal profile matters: In reported cases, CIDP developed 4-22 years AFTER MS diagnosis with clear new peripheral symptoms 3
• Diagnostic confirmation needed: Electrodiagnostic evidence of peripheral nerve demyelination is mandatory, along with clinical progression for >2 months 1, 6
• CSF protein elevation: Cerebrospinal fluid protein typically increases significantly (70 to 145 mg/dL) when CIDP develops 3
• Imaging changes: New cranial nerve and spinal root enhancement without intraparenchymal enhancement may occur 3

Critical Diagnostic Pitfall to Avoid

Do not confuse CNS demyelination (MS) with peripheral demyelination (CIDP) based solely on cognitive symptoms or medication side effects. 1, 2 The pregabalin and clonazepam this patient receives can contribute to cognitive impairment, and brain fog is a well-recognized manifestation of MS itself 4.

What Should Be Done Instead

Focus diagnostic efforts on optimizing MS management:

• Assess MS disease activity: Obtain brain MRI with gadolinium to evaluate for new T2 lesions or enhancement indicating breakthrough disease activity 7, 5, 8
• Evaluate medication effects: Pregabalin 150 mg twice daily can cause cognitive impairment; consider dose adjustment or alternative neuropathic pain management 4
• Monitor MS progression: Use Expanded Disability Status Scale (EDSS) scoring to document any disability progression 5, 8
• Consider DMT optimization: If breakthrough activity is present, escalation to high-efficacy disease-modifying therapy may be warranted 7